79779
document
Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations .
79780
Intervention_Pharmacological
salicylate
79781
Intervention_Pharmacological
Acetylsalicylic acid
79782
Intervention_Pharmacological
enteric-coated ASA
79783
Intervention_Pharmacological
compressed ASA tablets ( cASA )
79784
Intervention_Pharmacological
ecASA
79785
Intervention_Pharmacological
sodium salicylate
79786
Intervention_Pharmacological
ecASA
79787
Intervention_Pharmacological
cASA
79788
Intervention_Pharmacological
ASA
79789
Intervention_Pharmacological
ASA
79790
Outcome_Other
maximum effect
79791
Outcome_Physical
plasma ASA level and the maximum effect
79792
Participant_Sample-size
12
79793
Participant_Sex
male